These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 26568545)

  • 1. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.
    Iberri DJ; Colevas AD
    Oncologist; 2015 Dec; 20(12):1393-403. PubMed ID: 26446236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is EGFR really a therapeutic target in head and neck cancers?
    Agarwal V; Subash A; Nayar RC; Rao V
    J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
    Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
    Mehra R; Cohen RB; Harari PM
    Curr Oncol Rep; 2008 Mar; 10(2):176-84. PubMed ID: 18377832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.
    Ugurluer G; Ozsahin M
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1637-54. PubMed ID: 25134724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
    Schmitt NC; Trivedi S; Ferris RL
    Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):511-24. PubMed ID: 21504318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.
    Hoellein A; Pickhard A; von Keitz F; Schoeffmann S; Piontek G; Rudelius M; Baumgart A; Wagenpfeil S; Peschel C; Dechow T; Bier H; Keller U
    Oncotarget; 2011 Aug; 2(8):599-609. PubMed ID: 21865609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
    Mehra R; Cohen RB; Burtness BA
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):742-50. PubMed ID: 18997665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
    Herbst RS; Kim ES; Harari PM
    Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
    Ansell A; Jedlinski A; Johansson AC; Roberg K
    J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.